Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

Virology Journal

Volumn 8, Issue , 2011, Pages

  Wang, Shaoyang ^a   Huang, Dedong ^a   Sun, Shunlai ^a   Ma, Weimin ^a   Zhen, Qin ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; ALPHA INTERFERON; IL10 PROTEIN, HUMAN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; DNA SEQUENCE; GENETICS; IMMUNOLOGY; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

HEPATITIS B VIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENE FREQUENCY; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 78651556169     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-28     Document Type: Article

References (27)

1. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. MJ Sonneveld V Rijckborst CA Boucher BE Hansen HL Janssen, Hepatology 2010 52 1251 1257 10.1002/hep.23844 20830787
2. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. X Liang S Bi W Yang L Wang G Cui F Cui Y Zhang J Liu X Gong Y Chen F Wang H Zheng J Guo Z Jia J Ma H Wang H Luo L Li S Jin SC Hadler Y Wang, Vaccine 2009 27 6550 6557 10.1016/j.vaccine.2009.08. 048 19729084
3. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. MC Kew, Pathol Biol (Paris) 2010 58 273 277 20378277
4. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. GK Lau T Piratvisuth KX Luo P Marcellin S Thongsawat G Cooksley E Gane MW Fried WC Chow SW Paik WY Chang T Berg R Flisiak P McCloud N Pl (Pubitemid 41007823)
5. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. HL Janssen M van Zonneveld H Senturk S Zeuzem US Akarca Y Cakaloglu C Simon TM So G Gerken RA de Man HG Niesters P Zondervan B Hansen SW Schalm, Lancet 2005 365 123 129 10.1016/S0140-6736(05)17701-0 15639293 (Pubitemid 40091801)
6. The treatment of chronic viral hepatitis. JH Hoofnagle AM di Bisceglie, N Engl J Med 1997 336 347 356 10.1056/NEJM199701303360507 9011789
7. Current treatment strategies for chronic hepatitis B and C. OS Lin EB Keeffe, Annu Rev Med 2001 52 29 49 10.1146/annurev.med.52.1.29 11160766 (Pubitemid 32195313)
8. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. QM Gong XF Kong ZT Yang J Xu L Wang XH Li GD Jin J Gao DH Zhang JH Jiang ZM Lu XX Zhang, J Viral Hepat 2009 16 674 680 10.1111/j.1365-2893.2009.01130.x 19714778
9. Polymorphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients. HY Xie WL Wang MY Yao SF Yu XN Feng J Jin ZJ Jiang LM Wu SS Zheng, Arch Med Res 2008 39 420 428 10.1016/j.arcmed.2008.01.003 18375254
10. Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. XX He Y Chang HJ Jiang F Tang FY Meng QH Xie PY Li YH Song JS Lin, ral Immunol 2010 23 251 257
11. Tumour necrosis factor-alpha promoter region polymorphisms affect the course of spontaneous HBsAg clearance. PC Kao JF Wu YH Ni YT Lin HL Chen SH Hsu HY Hsu MH Chang, Liver Int 2010 30 1448 1453 10.1111/j.1478-3231.2010.02340.x 20825556
12. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B. SJ Lin PY Shu C Chang AK Ng CP Hu, J Immunol 2003 171 4708 4716 14568946 (Pubitemid 37310588)
13. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. JF Wu TC Wu CH Chen YH Ni HL Chen HY Hsu MH Chang, Gastroenterology 2010 138 165 172 e161-163 10.1053/j.gastro.2009.09.018 19782084
14. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. AL Truelove TK Oleksyk S Shrestha CL Thio JJ Goedert SM Donfield GD Kirk DL Thomas SJ O'Brien MW Smith, Int J Immunogenet 2008 35 255 264 10.1111/j.1744-313X.2008.00770.x 18479293 (Pubitemid 351678694)
15. Properties and functions of interleukin-10. TR Mosmann, Adv Immunol 1994 56 1 26 full-text 8073945 (Pubitemid 24242221)
16. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. J Eskdale V Keijsers T Huizinga G Gallagher, Genes Immun 1999 1 151 155 10.1038/sj.gene.6363656 11196662 (Pubitemid 129627293)
17. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. S Miyazoe K Hamasaki K Nakata Y Kajiya K Kitajima K Nakao M Daikoku H Yatsuhashi M Koga M Yano K Eguchi, Am J Gastroenterol 2002 97 2086 2092 10.1111/j.1572-0241.2002. 05926.x 12190181
18. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. CJ Edwards-Smith JR Jonsson DM Purdie A Bansal C Shorthouse EE Powell, Hepatology 1999 30 526 530 10.1002/hep.510300207 10421663 (Pubitemid 29357520)
19. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. XM Peng YS Huang HH Ma L Gu QF Xie ZL Gao, Liver Int 2006 26 326 333 10.1111/j.1478-3231.2005.01241.x 16584395 (Pubitemid 43349323)
20. Noncytolytic control of viral infections by the innate and adaptive immune response. LG Guidotti FV Chisari, Annu Rev Immunol 2001 19 65 91 10.1146/annurev.immunol.19.1.65 11244031 (Pubitemid 32368030)
21. Genetic influence on cytokine production in meningococcal disease. RG Westendorp JA Langermans TW Huizinga CL Verweij A Sturk, Lancet 1997 349 1912 1913 10.1016/S0140-6736(05)63910-4 9217780 (Pubitemid 27270137)
22. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. PK Constantini M Wawrzynowicz-Syczewska M Clare A Boron-Kaczmarska IG McFarlane ME Cramp PT Donaldson, Liver 2002 22 404 412 10.1034/j.1600-0676.2002. 01553.x 12390476 (Pubitemid 35331401)
23. Host genetic factors influence disease progression in chronic hepatitis C. EE Powell CJ Edwards-Smith JL Hay AD Clouston DH Crawford C Shorthouse DM Purdie JR Jonsson, Hepatology 2000 31 828 833 10.1053/he.2000.6253 10733535 (Pubitemid 30169926)
24. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. DF Fiorentino A Zlotnik P Vieira TR Mosmann M Howard KW Moore A O'Garra, J Immunol 1991 146 3444 3451 1827484
25. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. FY Yue R Dummer R Geertsen G Hofbauer E Laine S Manolio G Burg, Int J Cancer 1997 71 630 637 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E 9178819 (Pubitemid 27239375)
26. The immune response during hepatitis B virus infection. A Bertoletti AJ Gehring, J Gen Virol 2006 87 1439 1449 10.1099/vir.0.81920-0 16690908 (Pubitemid 43827198)
27. Immunology of hepatitis B infection. MC Jung GR Pape, Lancet Infect Dis 2002 2 43 50 10.1016/S1473-3099(01)00172-4 11892495 (Pubitemid 36109305)